CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($) $ in Millions		Common Stock		Treasury Stock at Cost	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balances at beginning of period at Dec. 31, 2019		$ 0.9		$ (79.7)	$ 322.8	$ (15.5)	$ (474.4)	$ (245.9)
Balances at beginning of period (in shares) at Dec. 31, 2019		84,103,108
Increase (Decrease) in Stockholders' Deficit
Changes in accumulated other comprehensive gain (loss)						(3.0)		(3.0)
Stock-based compensation					2.7			2.7
Issuance of restricted stock, net (in shares)		2,858,421
Purchase of shares				(0.7)				(0.7)
Purchase of shares (in shares)		(199,520)
Net income (loss)							0.1	0.1
Balances at end of period at Mar. 31, 2020	[1]	$ 0.9		(80.4)	325.5	(18.5)	(474.3)	(246.8)
Balances at end of period (in shares) at Mar. 31, 2020	[1]	86,762,009
Balances at beginning of period at Dec. 31, 2020		$ 1.0		(80.7)	333.8	(6.5)	(460.0)	$ (212.4)
Balances at beginning of period (in shares) at Dec. 31, 2020		86,847,797						86,847,797
Increase (Decrease) in Stockholders' Deficit
Changes in accumulated other comprehensive gain (loss)						4.3		$ 4.3
Stock-based compensation					3.1			3.1
Issuance of restricted stock, net (in shares)		666,127
Purchase of shares				(6.6)				(6.6)
Purchase of shares (in shares)		(397,186)
Net income (loss)							9.6	9.6
Balances at end of period at Mar. 31, 2021	[2]	$ 1.0		$ (87.3)	$ 336.9	$ (2.2)	$ (450.4)	$ (202.0)
Balances at end of period (in shares) at Mar. 31, 2021		87,116,738	[2]					87,116,738

[1] Included in outstanding shares as of March 31, 2020 are 5,292,277 non-vested shares of restricted stock awards  granted to employees and directors.

[2] Included in outstanding shares as of March 31, 2021 are 4,423,885 non-vested shares of restricted stock awards granted to employees and directors.